Form 4 for IBIO iBio, Inc.
Accepted 2023-01-24 00:00:00 ET · period of report 2023-01-20 · accession 0001104659-23-006184 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-24 | 2023-01-20 | IBIO | Brenner Martin | CSO, Interim CEO | A - Grant | $0.00 | +130.0K | 225.3K | +136% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-20 | A | A | 130,000 | $0.00 | 225,348 | D | — | — | (F1) Consists of 130,000 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 130,000 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 130,000 RSUs vest pro rata over a twelve- month period, such vesting to terminate if Dr. Brenner is no longer the Company's Interim Chief Executive Officer. |